Found: 52
Select item for more details and to access through your institution.
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2014, v. 14, n. 3, p. 169, doi. 10.1016/j.clbc.2013.10.016
- By:
- Publication type:
- Article
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 1, p. 53, doi. 10.1007/s10549-020-05817-w
- By:
- Publication type:
- Article
Apoptosis: mechanisms and implications for cancer therapeutics.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 197, doi. 10.1007/s11523-006-0034-1
- By:
- Publication type:
- Article
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 2, p. 284, doi. 10.1007/s10637-023-01342-x
- By:
- Publication type:
- Article
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 76, doi. 10.1007/s10637-018-0602-0
- By:
- Publication type:
- Article
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 616, doi. 10.1007/s10637-017-0442-3
- By:
- Publication type:
- Article
Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 341, doi. 10.1007/s10637-014-0183-5
- By:
- Publication type:
- Article
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 6, p. 1236, doi. 10.1007/s10637-014-0145-y
- By:
- Publication type:
- Article
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 8, p. 787, doi. 10.1007/s00262-014-1547-6
- By:
- Publication type:
- Article
Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 3, p. 530, doi. 10.1111/bcp.13817
- By:
- Publication type:
- Article
Case Report of CCDC149–ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma.
- Published in:
- Thyroid, 2022, v. 32, n. 12, p. 1580, doi. 10.1089/thy.2022.0389
- By:
- Publication type:
- Article
Predicting Pathologic Lymph Node Positivity in cN0 Pharynx and Larynx Cancers.
- Published in:
- Laryngoscope, 2023, v. 133, n. 7, p. 1660, doi. 10.1002/lary.30358
- By:
- Publication type:
- Article
Metabolism of patupilone in patients with advanced solid tumor malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 605, doi. 10.1007/s10637-012-9838-2
- By:
- Publication type:
- Article
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 3, p. 1065, doi. 10.1007/s10637-011-9642-4
- By:
- Publication type:
- Article
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
- Published in:
- PLoS ONE, 2019, v. 14, n. 9, p. 1, doi. 10.1371/journal.pone.0221994
- By:
- Publication type:
- Article
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
- Published in:
- Journal of Cellular & Molecular Medicine, 2010, v. 14, n. 10, p. 2448, doi. 10.1111/j.1582-4934.2009.00832.x
- By:
- Publication type:
- Article
Plinabulin Improves Survival and Duration of Response in Advanced Non-Small Cell Lung Cancer.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2017, v. 8, p. 35
- By:
- Publication type:
- Article
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs.
- Published in:
- FASEB Journal, 2003, v. 17, n. 9, p. 1144, doi. 10.1096/fj.02-1053fje
- By:
- Publication type:
- Article
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 6, p. 1113, doi. 10.1007/s00280-014-2572-z
- By:
- Publication type:
- Article
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 6, p. 1241, doi. 10.1007/s00280-014-2602-x
- By:
- Publication type:
- Article
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 1, p. 77, doi. 10.1007/s00280-014-2479-8
- By:
- Publication type:
- Article
Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
- Published in:
- 2013
- By:
- Publication type:
- Report
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 1, p. 35, doi. 10.1007/s00280-012-1963-2
- By:
- Publication type:
- Article
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 4, p. 751, doi. 10.1007/s00280-010-1372-3
- By:
- Publication type:
- Article
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 2, p. 287, doi. 10.1007/s00280-008-0869-5
- By:
- Publication type:
- Article
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
- By:
- Publication type:
- Article
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 2, p. 165, doi. 10.1007/s00280-006-0255-0
- By:
- Publication type:
- Article
Bromodomain inhibitors a decade later: a promise unfulfilled?
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Bromodomain inhibitors a decade later: a promise unfulfilled?
- Published in:
- 2020
- By:
- Publication type:
- Editorial
A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment.
- Published in:
- Pharmacotherapy, 2014, v. 34, n. 5, p. 440, doi. 10.1002/phar.1371
- By:
- Publication type:
- Article
Comparative impact of grade on mortality across salivary cancers: A novel, unifying staging system.
- Published in:
- Head & Neck, 2023, v. 45, n. 8, p. 2028, doi. 10.1002/hed.27429
- By:
- Publication type:
- Article
Variations in the association of grade with survival across the head and neck cancer landscape.
- Published in:
- Head & Neck, 2021, v. 43, n. 4, p. 1105, doi. 10.1002/hed.26566
- By:
- Publication type:
- Article
Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification.
- Published in:
- Head & Neck, 2018, v. 40, n. 6, p. 1228, doi. 10.1002/hed.25100
- By:
- Publication type:
- Article
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 4, p. 517, doi. 10.1007/s11523-023-00965-7
- By:
- Publication type:
- Article
Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Are we ready to move away from nature?: the rapamycin story.
- Published in:
- 2011
- By:
- Publication type:
- journal article
The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.
- Published in:
- 2011
- By:
- Publication type:
- journal article
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
- Published in:
- 2020
- By:
- Publication type:
- journal article
Quantitative survival impact of composite treatment delays in head and neck cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Impact of insurance on survival in patients < 65 with head & neck cancer treated with radiotherapy.
- Published in:
- Clinical Otolaryngology, 2020, v. 45, n. 1, p. 63, doi. 10.1111/coa.13467
- By:
- Publication type:
- Article
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
- Published in:
- Oncology, 2019, v. 97, n. 2, p. 102, doi. 10.1159/000500571
- By:
- Publication type:
- Article
Phase 1 dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors.
- Published in:
- OncoTargets & Therapy, 2017, v. 10, p. 3177, doi. 10.2147/OTT.S128547
- By:
- Publication type:
- Article